Ferrante M - Search Results

1

Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.

Verstockt B, Volk V, Jaeckel C, Alsoud D, Sabino J, Nikolaus S, Outtier A, Krönke N, Feuerhake F, De Hertogh G, Rosenstiel P, Vermeire S, Schreiber S, Ferrante M, Aden K. Verstockt B, et al. Among authors: ferrante m. Aliment Pharmacol Ther. 2022 Jul;56(2):282-291. doi: 10.1111/apt.16955. Epub 2022 Apr 28. Aliment Pharmacol Ther. 2022. PMID: 35484689

2

Protein-losing enteropathy in Crohn's disease.

Ferrante M, De Hertogh G, Penninckx F, Van Assche G. Ferrante M, et al. Clin Gastroenterol Hepatol. 2005 Jun;3(6):A25. doi: 10.1016/s1542-3565(05)00243-0. Clin Gastroenterol Hepatol. 2005. PMID: 15952090 No abstract available.

3

Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn's disease.

Hlavaty T, Persoons P, Vermeire S, Ferrante M, Pierik M, Van Assche G, Rutgeerts P. Hlavaty T, et al. Among authors: ferrante m. Inflamm Bowel Dis. 2006 Mar;12(3):199-204. doi: 10.1097/01.MIB.0000217768.75519.32. Inflamm Bowel Dis. 2006. PMID: 16534421

4

The value of myenteric plexitis to predict early postoperative Crohn's disease recurrence.

Ferrante M, de Hertogh G, Hlavaty T, D'Haens G, Penninckx F, D'Hoore A, Vermeire S, Rutgeerts P, Geboes K, van Assche G. Ferrante M, et al. Gastroenterology. 2006 May;130(6):1595-606. doi: 10.1053/j.gastro.2006.02.025. Gastroenterology. 2006. PMID: 16697723

5

Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis.

Moskovitz DN, Van Assche G, Maenhout B, Arts J, Ferrante M, Vermeire S, Rutgeerts P. Moskovitz DN, et al. Among authors: ferrante m. Clin Gastroenterol Hepatol. 2006 Jun;4(6):760-5. doi: 10.1016/j.cgh.2006.04.001. Epub 2006 May 22. Clin Gastroenterol Hepatol. 2006. PMID: 16716758

6

The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease.

Ferrante M, Pierik M, Henckaerts L, Joossens M, Claes K, Van Schuerbeek N, Vlietinck R, Rutgeerts P, Van Assche G, Vermeire S. Ferrante M, et al. Inflamm Bowel Dis. 2006 Sep;12(9):870-8. doi: 10.1097/01.mib.0000235095.01608.10. Inflamm Bowel Dis. 2006. PMID: 16954806

7

Predictors of early response to infliximab in patients with ulcerative colitis.

Ferrante M, Vermeire S, Katsanos KH, Noman M, Van Assche G, Schnitzler F, Arijs I, De Hertogh G, Hoffman I, Geboes JK, Rutgeerts P. Ferrante M, et al. Inflamm Bowel Dis. 2007 Feb;13(2):123-8. doi: 10.1002/ibd.20054. Inflamm Bowel Dis. 2007. PMID: 17206703 Clinical Trial.

8

Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors.

Hlavaty T, Ferrante M, Henckaerts L, Pierik M, Rutgeerts P, Vermeire S. Hlavaty T, et al. Among authors: ferrante m. Inflamm Bowel Dis. 2007 Apr;13(4):372-9. doi: 10.1002/ibd.20024. Inflamm Bowel Dis. 2007. PMID: 17206723

9

Protein-losing enteropathy in Crohn's disease.

Ferrante M, Penninckx F, De Hertogh G, Geboes K, D'Hoore A, Noman M, Vermeire S, Rutgeerts P, Van Assche G. Ferrante M, et al. Acta Gastroenterol Belg. 2006 Oct-Dec;69(4):384-9. Acta Gastroenterol Belg. 2006. PMID: 17343081

10

New serological markers in inflammatory bowel disease are associated with complicated disease behaviour.

Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, Norman GL, Altstock RT, Van Steen K, Rutgeerts P, Van Assche G, Vermeire S. Ferrante M, et al. Gut. 2007 Oct;56(10):1394-403. doi: 10.1136/gut.2006.108043. Epub 2007 Apr 24. Gut. 2007. PMID: 17456509 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

924 results

Search Page